Xeris Pharmaceuticals, Inc. | Company Profile - Revenue, Headcount, Tech Stack, Contacts

Company Directory for Xeris Pharmaceuticals, Inc.

Team Bitscale

12 Mar 2026 — 1 min read

Xeris Pharmaceuticals, Inc.

Overview

Founded in 2005 by Steve Prestrelski and John Kinzell, Xeris Pharmaceuticals, now Xeris Biopharma Holdings, Inc., is a biopharmaceutical organization headquartered in Chicago, Illinois. The company is dedicated to advancing patient care by developing and commercializing innovative therapeutic products, specializing in ready-to-use injectable formulations that aim to enhance convenience and treatment effectiveness.

Xeris's portfolio includes FDA-approved injectable therapies such as Gvoke, as well as treatments for rare diseases including primary periodic paralysis and Cushing's syndrome. Its proprietary formulation technology and 40 patent holdings position it as a leader in sustained-release medication. Strategic collaborations and acquisitions, like the 2020 integration of Strongbridge Biopharma, have further expanded the scope of its rare disease offerings, and the company continues to invest in innovative drug delivery platforms and pipeline development.

Basic Information

Industry	pharmaceuticals
Founded	2005
Revenue	$203.1M
Headquarters	1375 W Fulton St, Suite 1300, Chicago, Illinois 60607, United States
Languages	English

Contact Details

Phone: +1 844-445-5704
Website: xerispharma.com
LinkedIn: linkedin.com/company/xeris-pharmaceuticals

Key Focus Areas & Initiatives

Biotechnology
Life sciences
Pharmaceutical manufacturing
Medical devices
Patient treatment improvement
Injectable drug delivery
Proprietary formulation platforms
Financial performance
Drug stability
Biopharmaceutical manufacturing
Biotech pipeline
Product development
Patent protection
Long-term product development
Global partnerships
Regulatory strategy
Clinical development
Regulatory approval
Therapeutic innovation
Innovative drug formulations
Rare disease therapies
Scalable manufacturing
Product commercialization
Patent portfolio
Injectable therapies

Technologies Used

AI
Adobe Marketing Cloud
Amazon AWS
Amazon SES
Analyzer
Atlassian Cloud
CloudFlare Hosting
Cloudflare DNS
Drupal
HPLC
IBM Data Warehouse
ISO+™
IoT
Lytics
Micro
Microsoft Excel
Mimecast
Outlook
Remote
SQL
Salesforce
Salesforce CRM Analytics
Sendgrid
Slack
Tor
Wagtail CMS

Affiliated Organizations & Regional Branches

GTM Strategy: The Complete Guide (Framework, Examples & B2B Playbook)

Most things labeled a “GTM strategy” are really a channel checklist wearing a nice slide template. They are activity plans, not a coherent answer to how the business will create, capture, and deliver value for a specific buyer in a specific market. This is written for B2B founders, product marketers,

How Scrut.io Built a Compliance-Signal GTM Machine with Bitscale

Scrut Automation simplifies continuous compliance for cloud-native companies, helping them achieve ISO 27001, SOC 2, PCI DSS, and GDPR compliance 5x faster — with real-time risk monitoring and automated evidence collection.

Clay API Limits, Authentication & Rate Limits Explained

Your enrichment workflow ran perfectly on 50 test records. Then you pointed it at 10,000 contacts and everything collapsed: 429 errors, duplicate CRM writes, and a credit balance that evaporated overnight. The Clay API usually is not the root cause. The root cause is treating authentication, rate limits, and

GTM Data Stack for US Outbound Teams

Outbound has changed. Spray-and-pray cadences that worked five years ago now burn through contact lists, damage sender reputation, and leave revenue teams short on pipeline. What separates high-performing US outbound teams in 2026 is not effort or headcount. It is the quality, governance, and architecture of the GTM Data Stack.